CLINICAL_TRIALS
trial_result
· 2007-02-21
Clinical Trial Update: Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab [Phase 3]
Summary
A Phase 3 trial evaluated the safety of eculizumab in patients with paroxysmal nocturnal hemoglobinuria. The study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hemoglobinuria, Paroxysmal | Phase 3 | Status: COMPLETED